SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 1997
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516-286-5800)
N/A
(Former name or former address, if changed since last report.)
<PAGE>
ITEM 5. OTHER MATERIAL EVENTS
On June 13, 1997 Mr. William Kuger, Vice President of Finance and Chief
Accounting Officer resigned from the Company. He was replaced by Vincent H.
Pontillo as Controller and Chief Accounting Officer.
EXHIBIT INDEX
Current Report on Form 8-K
of
Biopharmaceutics, Inc.
Date of Report: August 1, 1997
Exhibit:
None
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Edward Fine
Edward Fine
President, Chief Executive Officer
(Signature)
Dated: August 1, 1997
